Literature DB >> 16510044

Triglycerides and remnant particles as risk factors for coronary artery disease.

Takamitsu Nakamura1, Kiyotaka Kugiyama.   

Abstract

Coronary artery disease (CAD) is the largest cause of morbidity and mortality in the world. A relationship between CAD and elevated levels of low-density lipoprotein cholesterol has been established. However, risk assessment limited to low-density lipoprotein fails to identify a significant portion of patients at risk for CAD. Remnant lipoproteins, derived from very low-density lipoprotein and chylomicrons, have been considered atherogenic. Recently, a simple and reliable immunoaffinity separation method for the isolation of remnant-like particles (RLP) has been developed. It has been shown that RLP cholesterol levels are significantly correlated with CAD, and thus cellular mechanisms have been determined by which RLP cholesterol causes progression of atherosclerosis. Measurement of RLP cholesterol is useful for the assessment of risk and the evaluation of therapy in patients at risk for CAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510044     DOI: 10.1007/s11883-006-0047-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  17 in total

1.  Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.

Authors:  D T Stein; S Devaraj; D Balis; B Adams-Huet; I Jialal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

2.  Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease.

Authors:  K Kugiyama; H Doi; K Takazoe; H Kawano; H Soejima; Y Mizuno; R Tsunoda; T Sakamoto; T Nakano; K Nakajima; H Ogawa; S Sugiyama; M Yoshimura; H Yasue
Journal:  Circulation       Date:  1999-06-08       Impact factor: 29.690

3.  Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.

Authors:  Takamitsu Nakamura; Hajime Takano; Ken Umetani; Ken-ichi Kawabata; Jyun-ei Obata; Yoshinobu Kitta; Yasushi Kodama; Akira Mende; Yoshihide Ichigi; Daisuke Fujioka; Yukio Saito; Kiyotaka Kugiyama
Journal:  Atherosclerosis       Date:  2005-02-16       Impact factor: 5.162

4.  Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.

Authors:  Pernette R W de Sauvage Nolting; Marcel B Twickler; Geesje M Dallinga-Thie; Rudolf J A Buirma; Barbara A Hutten; John J P Kastelein
Journal:  Circulation       Date:  2002-08-13       Impact factor: 29.690

5.  Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study.

Authors:  J R McNamara; P K Shah; K Nakajima; L A Cupples; P W Wilson; J M Ordovas; E J Schaefer
Journal:  Clin Chem       Date:  1998-06       Impact factor: 8.327

6.  Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease.

Authors:  S Devaraj; G Vega; R Lange; S M Grundy; I Jialal
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

7.  Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus.

Authors:  Hironobu Fukushima; Seigo Sugiyama; Osamu Honda; Shunichi Koide; Shinichi Nakamura; Tomohiro Sakamoto; Michihiro Yoshimura; Hisao Ogawa; Daisuke Fujioka; Kiyotaka Kugiyama
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

8.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

9.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries.

Authors:  K Kugiyama; H Doi; T Motoyama; H Soejima; K Misumi; H Kawano; O Nakagawa; M Yoshimura; H Ogawa; T Matsumura; S Sugiyama; T Nakano; K Nakajima; H Yasue
Journal:  Circulation       Date:  1998-06-30       Impact factor: 29.690

10.  Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels.

Authors:  K Nakajima; T Saito; A Tamura; M Suzuki; T Nakano; M Adachi; A Tanaka; N Tada; H Nakamura; E Campos
Journal:  Clin Chim Acta       Date:  1993-12-31       Impact factor: 3.786

View more
  6 in total

1.  Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase.

Authors:  Li-Li Shen; Hong Liu; Jiahe Peng; Lin Gan; Li Lu; Qian Zhang; Liangpeng Li; Fengtian He; Yu Jiang
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

2.  Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice.

Authors:  Linda S Zhang; Min Xu; Qing Yang; Robert O Ryan; Philip Howles; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-01-23       Impact factor: 4.052

3.  Lipid-regulating effect of traditional chinese medicine: mechanisms of actions.

Authors:  Wei-Jian Bei; Jiao Guo; Hai-Yun Wu; Yang Cao
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-07       Impact factor: 2.629

4.  Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA₂ in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome.

Authors:  Hyo Sun Lee; Chang Hee Jung; Sung Rae Kim; Hak Chul Jang; Cheol Young Park
Journal:  Endocrinol Metab (Seoul)       Date:  2016-03

Review 5.  Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida
Journal:  Int J Mol Sci       Date:  2019-03-08       Impact factor: 5.923

6.  Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance.

Authors:  Jin Chen; Jie Kuang; Xiaoyu Tang; Ling Mao; Xin Guo; Qin Luo; Daoquan Peng; Bilian Yu
Journal:  Lipids Health Dis       Date:  2020-06-10       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.